Adaptive Radiation for Abdominopelvic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, you cannot be on any other investigational drugs while participating in this trial.
Is adaptive radiation therapy safe for treating abdominopelvic cancer?
Research shows that stereotactic body radiation therapy (SBRT), a form of adaptive radiation, is generally safe for treating various cancers, including abdominopelvic tumors. Studies report mild side effects like increased vaginal discharge, with no long-term side effects observed in some cases, indicating a safe toxicity profile.12345
How is Adaptive Stereotactic Body Radiation Therapy (SBRT) different from other treatments for abdominopelvic cancer?
Adaptive Stereotactic Body Radiation Therapy (SBRT) is unique because it uses real-time imaging, like MRI or CT, to adjust the radiation plan daily, allowing for precise targeting of tumors while minimizing damage to nearby organs. This adaptability is particularly beneficial for treating tumors in the abdomen where organs can move, improving safety and effectiveness compared to traditional radiation therapies.56789
What data supports the effectiveness of the treatment Adaptive Stereotactic Body Radiation for abdominopelvic cancer?
Research shows that adaptive stereotactic body radiation therapy (SBRT) is feasible and potentially beneficial for treating tumors in the abdomen and pelvis. Studies indicate that using advanced imaging techniques, like MR-guided systems, can improve the precision and effectiveness of SBRT by adapting to changes in the patient's anatomy during treatment.5781011
Who Is on the Research Team?
Joshua E. Meyer
Principal Investigator
Fox Chase Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with metastatic cancer in the abdomen or pelvis, who have at least one lesion not treated by radiation or growing. They must have acceptable liver and kidney function, a certain level of blood cells, an ECOG performance status of 0 or 1, and be expected to live at least another year. Pregnant women, those with too many metastases (6+), prior radiotherapy on target lesions, uncontrolled illnesses, or severe toxicity from past treatments are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Radiation
Adaptive stereotactic body radiation (SBRT) treatment with dose escalation to find the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
Follow-up
Participants are monitored for safety and effectiveness after treatment, assessing for severe (grade 3) toxicity
What Are the Treatments Tested in This Trial?
Interventions
- Adaptive Stereotactic Body Radiation
Adaptive Stereotactic Body Radiation is already approved in United States, European Union, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Fox Chase Cancer Center
Lead Sponsor